These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8851573)

  • 1. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.
    Reigner BG; Welker HA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):575-80. PubMed ID: 8851573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.
    Uehlinger DE; Schaedeli F; Kinzig M; Sörgel F; Frey FJ
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1903-9. PubMed ID: 8843301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
    Kim MK; Nightingale C; Nicolau D
    Clin Pharmacokinet; 2003; 42(11):985-96. PubMed ID: 12908854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
    Schrenzel J; Cerruti F; Herrmann M; Leemann T; Weidekamm E; Portmann R; Hirschel B; Lew DP
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1219-24. PubMed ID: 8092817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.
    Bertino JS; Nafziger AN
    Antimicrob Agents Chemother; 1996 Mar; 40(3):789-91. PubMed ID: 8851614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
    Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of fleroxacin in horses.
    Rebuelto M; Otero P; Albarellos G; Ambros L; Kreil V; Waxman S; Montoya L; Hallu R
    J Vet Pharmacol Ther; 2000 Apr; 23(2):103-5. PubMed ID: 10849255
    [No Abstract]   [Full Text] [Related]  

  • 13. Overview of the pharmacokinetics of fleroxacin.
    Nightingale CH
    Am J Med; 1993 Mar; 94(3A):38S-43S. PubMed ID: 8452184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.
    Salem AH; Giranda VL; Mostafa NM
    Clin Pharmacokinet; 2014 May; 53(5):479-88. PubMed ID: 24452810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
    Kodati D; Kotakonda HK; Yellu N
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):573-581. PubMed ID: 27535556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fleroxacin pharmacokinetics in healthy volunteers and impaired renal function.
    Höffler D; Koeppe P; Metz R; Pech M; Sörgel F
    J Chemother; 1989 Jul; 1(4 Suppl):558-60. PubMed ID: 16312531
    [No Abstract]   [Full Text] [Related]  

  • 19. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of fleroxacin determined by biological method.
    Verbist L; Van Hecken A; De Schepper P
    J Chemother; 1989 Jul; 1(4 Suppl):572-3. PubMed ID: 16312537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.